Shrinking Optics. Unlocking Possibilities

GET CONNECTED
leadoptik.com

Team

Reza Khorasaninejad

CEO & Founder

Leadoptik

Company details

Last Inch Assessment (LIA) Technology from LEADOPTIK is transforming real-time depth imaging and bridging the gap between diagnosis and therapy for early-stage lung cancer. LIA features an AI-powered imaging console and a single-use, image-guided biopsy needle. Its metasurface optics – 100 times thinner than a human hair – deliver 50 times higher resolution than legacy technologies. By enabling real-time differentiation between malignant and benign tissue, LIA empowers physicians to achieve precise diagnosis (during biopsy) and effective therapy (targeting cancerous areas for ablation or surgical resection).

Human HealthUnited StatesSeries A(+)DiagnosticsHard TechHealthcareHuman HealthHAX 2020

Company News

Leadoptik and Stanford Medicine to explore imaging in lung biopsy procedures

March 20, 2025
Yahoo Finance

Leadoptik Receives Investment from Applied Ventures – FinSMEs

June 20, 2023
FinSMEs

LEADOPTIK: $5 Million Secured To Build Early Lung Cancer Detection – Pulse 2.0

June 8, 2023
Pulse 2.0

Get In Touch with Leadoptik

Please tell us a little bit about yourself and why you'd like to get connected. Leadoptik + SOSV will follow up with you via email.

Hidden
Hidden
Hidden
Hidden
Opt-in checkbox


We don’t spam. Our Privacy Policy and Terms of Use apply.
* If you are interested in investing directly into SOSV's portfolio of privately held companies, or into SOSV's funds, you need to meet the SEC’s criteria for accredited investor status. As an individual, you can qualify as an accredited investor by either (a) having more than $200,000 in annual income for each of the past two years (or $300,000 with your spouse) and a reasonable expectation of earning the same this year or (b) having a net worth of at least $1 million (not including your principal residence). Learn More